



Please type a plus sign (+) inside this box



Attachment to Paper #4

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
			Application Number	10/006,882
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	December 10, 2001
			First Named Inventor	Meyer
			Group Art Unit	1645/1648
			Examiner Name	Chen, Stacy
Sheet	1	of	Attorney Docket Number	20695C-001900US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SBC	A1	US 4,783,407		Provost, et al.	11-08-1988	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
SBC	B1	PCT	WO 95/24468	A1	Merck & Co. Inc.	09-14-1995		
SBC	B2	PCT	WO 96/15231	A2	Immuno Aktiengesell schaft	05-23-1996		

Examiner Signature	Stacy B. Chen	Date Considered	August 22, 2003
-----------------------	---------------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1334364 v1



Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of

Complete if Known

Application Number	10/006,882
Filing Date	December 10, 2001
First Named Inventor	
Group Art Unit	1645/1648
Examiner Name	Chen, Stacy
Attorney Docket Number	20695C-001900US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
SBC	C1	André, <i>et al.</i> "Inactivated Candidate Vaccines for Hepatitis A" <i>Prog. Med. Virol.</i> (1990) Vol. 37, pp. 72-95.
	C2	Armstrong, <i>et al.</i> "Development of the Formalin-inactivated Hepatitis A Vaccine VAQTA™ From the Live Attenuated Virus Strain CR326F" <i>J. of Hepatology</i> (1993) Vol. 18, pp. 20-26.
	C3	Aunins, <i>et al.</i> "Reactor Development for the Hepatitis A Vaccine VAQTA™" <i>Animal Cell Technology</i> (1997) pp. 175-183.
	C4	Binn, <i>et al.</i> "Primary Isolation and Serial Passage of Hepatitis A Virus Strains in Primate Cell Cultures" <i>J. of Clinical Microbiology</i> (July 1984) Vol. 20(1), pp. 28-33.
	C5	Bishop, <i>et al.</i> "Rapid and Efficient Purification of Hepatitis A Virus From Cell Culture" <i>J. of Virological Methods</i> (1994) Vol. 47, pp. 203-216.
	C6	Bishop, <i>et al.</i> "Hepatitis A Virus Subviral Particles: Purification, Accumulation, and Relative Infectivity of Virions, Provirions, and Procapsids" <i>Arch Virol.</i> (1997) - Vol. 142, pp. 2147-2160.
	C7	Butler, M. A Comparative Review of Microcarriers Available for the Growth of Anchorage-dependent Animal Cells" <i>Animal Cell Biotechnology</i> , Ed. R.E. Spier and J.B. Griffiths (1988) Vol. 3, pp. 284-303.
	C8	Cohen, <i>et al.</i> "Hepatitis A Virus cDNA and Its RNA Transcripts are Infectious in Cell Culture" <i>J. of Virology</i> (October 1987), Vol. 61(10), pp. 3035-3039.
	C9	Flehmgig, <i>et al.</i> "Immunogenicity of a Hepatitis A Virus Vaccine" <i>J. of Medical Virology</i> (1987) Vol. 22, pp. 7-16.
	C10	Junker, <i>et al.</i> "Evaluation of a Microcarrier Process for Large-scale Cultivation of Attenuated Hepatitis A" <i>Cytotechnology</i> (1992) Vol. 9, pp. 173-187.
	C11	Kistner, <i>et al.</i> "Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine" <i>Vaccine</i> (1998) Vol. 16(9/10), pp. 960-968.
	C12	Lemon, <i>et al.</i> "Antigenic Structure of Hepatitis A Virus" <i>Molecular Aspects of Picornavirus and Detection</i> Ed. B.L. Semler and E. Ehrenfeld (1989) (1989) pp. 193-208.

Examiner Signature	Stacy B. Chen	Date Considered	August 22, 2003
-----------------------	---------------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1334364 v1

RECEIVED
APR 17 2002

RECEIVED
APR 17 2002

OLPE JCT7777
APR 15 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Application Number		10/006,882	
Filing Date		December 10, 2001	
First Named Inventor			
Group Art Unit		1645-1648	
Examiner Name		Chen, Stacy	
Attorney Docket Number		20695C-001900US	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
SBC	C13	Locarnini, <i>et al.</i> "Restricted Replication of Human Hepatitis A Virus in Cell Culture: Intracellular Biochemical Studies" <i>J. of Virology</i> (January 1981) Vol. 37(1), pp. 216-225.
↓	C14	Nasser, <i>et al.</i> "Production of Cytopathology in FRhK-4 Cells by BS-C-1-Passaged Hepatitis A Virus" <i>Applied and Environmental Microbiology</i> (December 1987) Vol. 53(12), pp. 2967-2971.
↓	C15	Simmonds, <i>et al.</i> "Persistently Infected Cultures as a Source of Hepatitis A Virus" <i>Applied and Environmental Microbiology</i> (April 1985) Vol. 49(4), pp. 749-755.
↓	C16	Widell, <i>et al.</i> "A Microcarrier Cell Culture System for Large Scale Production of Hepatitis A Virus" <i>J. of Virological Methods</i> (1984) Vol. 8, pp. 63-71.
↓	C17	Yokosawa, <i>et al.</i> "Affinity Chromatography of Trypsin and Related Enzymes" <i>J. of Biochem.</i> (1976) Vol. 79, pp. 757-763.

Examiner Signature	Stacy B. Chen	Date Considered	August 22, 2003
--------------------	---------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1334364 v1

RECEIVED
APR 17 2002
TECH CENTER 1000/2900

RECEIVED
APR 17 2002